ABSTRACT
Background: The Confederated Tribes of the Grand Ronde Community of Oregon began a Mobile Medication Unit (MMU) as part of their Great Circle Recovery Opioid Treatment Program (OTP) to address elevated rates of opioid use disorder (OUD) among American Indians and Alaska Natives in Oregon. The MMU provides methadone or buprenorphine for individuals with OUD, enrolled in the OTP, who are living either on the reservation or in surrounding rural communities. An implementation study describes the service through document review and qualitatively assesses patient and staff experiences and the perceived barriers and facilitators to mobile services.
Methods: Semi-structured qualitative interviews with patients (n=11), MMU staff (n=5), and the state opioid treatment authority (n=1) gathered details on the initiative’s development and operations. Provider interviews probed implementation experiences. Patient interviews focused on their experiences with the MMU and staff, changes in quality of life and recommendations for enhancing treatment. Interviews were transcribed and analysed using a Thematic Analysis approach.
Results: Staff themes identified two driving forces (i.e. staff desire for an inclusive approach to wellness that is accessible to all community members; the catalysts for the MMU), two steps toward MMU development (i.e. Tribal approvals and support; the construction and maintenance of community relationships) and two perspectives on MMU implementation and impact (i.e. initial implementation barriers; facilitators and observations of how the MMU reduced stigma associated with agonist therapy). Patients’ themes noted the MMU’s professional and ‘caring’ environment, accessible rural locations and general suggestions including culturally responsive ancillary services.
Conclusion: The Great Circle MMU enhanced access to opioid agonist therapy for people with OUD (i.e. American Indians/Alaska Natives, and non-natives) living in rural communities. The Confederated Tribes of Grand Ronde operates the first Tribally owned OTP MMU, grounded in cultural humility and committed to Tribal members and the great circle of the larger community.
Resource
Addressing Substance Use and Social Needs of People of Color with Substance Use Disorders
Key Points: In this brief, we highlight the experiences and practices of substance use treatment providers
and their human services partners when serving people of color. We selected providers who
focused on serving people of color, and this study was not intended to assess outcomes or
effectiveness of any of the practices highlighted.
- Treatment providers highlighted several practices that promoted active and positive
participation in their programs by people of color:- Incorporate the community’s cultural values into organizational structures and
treatment models. - Engage the community in designing programs and services and hire staff that
reflect the community. - Address the comprehensive health, social, and economic needs of
participants. - Incorporate harm reduction services and healing-centered approaches in the
continuum of care.
- Incorporate the community’s cultural values into organizational structures and
- Providers described several constraints when serving communities of color:
- Structural barriers such as poverty, racism, and differential access significantly
impede meeting clients’ social and economic needs. - Challenges retaining program staff with the appropriate language and cultural
skills. - A complex patchwork of funding streams.
- A lack of data and limited internal capacity for data analysis and program
evaluation.
- Structural barriers such as poverty, racism, and differential access significantly
- Providers emphasized that success required working with the strengths of the
communities they serve and that every community has protective factors. More
research is needed to understand how federal, state, and local policies and programs
can maximize the strengths of communities of varied backgrounds, while also
implementing evidence-based practices.
Implementation of medication for opioid use disorder treatment in Indian health clinics in California: A qualitative evaluation
Abstract
Introduction: American Indians and Alaska Native (AIAN) populations are disproportionately affected by opioid misuse. Medication for opioid use disorder (MOUD) is essential to decrease overdose events and overdose deaths. AIAN communities can benefit from MOUD programs that are housed within primary care clinics to improve treatment accessibility. This study aimed to gather information on the needs, barriers, and successes related to implementing MOUD programs in Indian health clinics (IHCs) offering primary care.
Methods: The study used the Reach, Effectiveness, Adoption, Implementation, and Maintenance Qualitative Evaluation for Systematic Translation (RE-AIM QuEST) evaluation framework to structure key informant interviews with clinic staff who received technical assistance for MOUD program implementation. The study incorporated RE-AIM dimensions into a semi-structured interview guide. We developed the coding approach for analyzing interview data using Braun and Clarke’s (2006) reflexive thematic analysis in qualitative research.
Results: Eleven clinics participated in the study. The research team conducted twenty-nine interviews with clinic staff. We found that inadequate education about MOUD, scant resources, and limited availability of AIAN providers adversely impacted reach. Challenges with integrating medical and behavioral care, patient-level barriers (e.g., rural conditions, geographical dispersion), and limited workforce capacity impacted MOUD effectiveness. Stigma at the clinic level was detrimental to MOUD adoption. Implementation was challenging due to a limited number of waivered providers, and the need for technical assistance and MOUD policies and procedures. Staff turnover and restricted physical infrastructure negatively influenced MOUD maintenance.
Conclusions: Clinical infrastructure should be strengthened. The integration of culture into clinic services must be embraced by staff to support MOUD adoption. Increased representation from AIAN clinical staff is needed to appropriately represent the population being served. Stigma at various levels must be addressed, and the multiple barriers that AIAN communities face must be considered in understanding MOUD program implementation and outcomes.
Community members and students may request access to this article by completing the form here.
Naloxone analogy and opioid overdose terminology preferences among rural caregivers: Differences by race
Abstract
Background: Despite national and state policies aimed at increasing naloxone access via pharmacies, opioid overdose death rates rose during the COVID-19 pandemic, particularly among Blacks and American Indians (AIs) in rural areas. Caregivers, or third parties who can administer naloxone during an overdose event, are important individuals in the naloxone administration cascade, yet no studies have explored rural caregivers’ opioid overdose terminology and naloxone analogy preferences or whether these preferences differ by race.
Objectives: To identify rural caregivers’ overdose terminology and naloxone analogy preferences and determine whether preferences differ by race.
Methods: A sample of 40 caregivers who lived with someone at high risk of overdose and used pharmacies in 4 largely rural states was recruited. Each caregiver completed a demographic survey and a 20- to 45-minute audio-recorded semi-structured interview that was transcribed, de-identified, and imported into a qualitative software package for thematic analysis by 2 independent coders using a codebook. Overdose terminology and naloxone analogy preferences were analyzed for differences by race.
Results: The sample was 57.5% white, 35% Black, and 7.5% AIs. Many participants (43%) preferred that pharmacists use the term “bad reaction” to refer to overdose events over the terms “accidental overdose” (37%) and “overdose” (20%). The majority of white and Black participants preferred “bad reaction” while AI participants preferred “accidental overdose.” For naloxone analogies, “EpiPen” was most preferred (64%), regardless of race. “Fire extinguisher” (17%), “lifesaver” (9.5%), and other analogies (9.5%) were preferred by some white and Black participants but not AI participants.
Conclusion: Our findings suggest that pharmacists should use the “bad reaction” term and “EpiPen” analogy when counseling rural caregivers about overdose and naloxone, respectively. Caregivers’ preferences varied by race, suggesting that pharmacists may want to tailor the terminology and analogy they use when discussing naloxone with caregivers.
Community members and students may request access to this article by completing the form here.
Diversity inclusion in United States opioid pharmacological treatment trials: A systematic review
Abstract: Pharmacological treatments for opioid use disorders (OUDs) may have mixed efficacy across diverse groups, i.e., sex/gender, race/ethnicity, and socioeconomic status (SES). The present systematic review aims to examine how diverse groups have been included in U.S. randomized clinical trials examining pharmacological treatments (i.e., methadone, buprenorphine, or naltrexone) for OUDs. PubMed was systematically searched according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The initial search yielded 567 articles. After exclusion of ineligible articles, 50 remained for the present review. Of the included articles, 14.0% (n = 7) reported both full (i.e., accounting for all participants) sex/gender and race/ethnicity information; only two of those articles also included information about any SES indicators. Moreover, only 22.0% (n = 11) reported full sex/gender information, and 42.0% (n = 21) reported full racial/ethnic information. Furthermore, only 10.0% (n = 5) reported that their lack of subgroup analyses or diverse samples was a limitation to their studies. Particularly underrepresented were American Indian/Alaska Native (AI/AN), Asian, Native Hawaiian/Other Pacific Islander (NH/OPI), and multiracial individuals. These results also varied by medication type; Black individuals were underrepresented in buprenorphine randomized controlled trials (RCTs) but were well represented in RCTs for methadone and/or naltrexone. In conclusion, it is critical that all people receive efficacious pharmacological care for OUDs given the ongoing opioid epidemic. Findings from the present review, however, support that participants from diverse or marginalized backgrounds are underrepresented in treatment trials, despite being at increased risk for disparities related to OUDs. Suggestions for future research are advanced.
Community members and students may request access to this article by completing the form here.
Deaths associated with opioids, race and ethnicity, and years of potential life lost in Washington State
Introduction: This study examined disparities in years of potential life lost (YPLL) related to opioid use among racial and ethnic groups adjusting for individual- and neighborhood-level characteristics.
Methods: The study obtained data on 5265 geocoded death records associated with opioid use from the Washington State Department of Health. Death certificates included information on race and ethnicity, sex, marital status, and educational attainment. We linked these records to neighborhood-level indicators of rurality, area deprivation, and access to opioid treatment programs. Generalized linear mixed models tested associations between racial and ethnic identity and YPLL controlling for other individual and neighborhood characteristics.
Results: Among all decedents from opioid-related causes, the study found that racial and ethnic minorities-including Black, American Indian/Alaska Native, Asian, Native Hawaiian or other Pacific Islander-multiracial, or Hispanic adults died at younger ages than did White adults (33 to 44 vs 45). In the fully adjusted models, the estimated mean for YPLL was higher for Asian or Native Hawaiian or other Pacific Islander, multiracial, and Hispanic adults compared to White adults. Accounting for educational attainment and marital status substantially reduced YPLL differences between groups, by as much as 40% in some cases. Conclusions: The study observed striking differences in YPLL related to opioid causes among racial and ethnic minorities. Accounting for social determinants of health greatly reduced YPLL across all groups but racial and ethnic disparities in YPLL remained significant. Understanding and alleviating additional causes of disparities in YPLL is warranted to abate the epidemic of opioid related deaths in the United States.
Community members and students may request access to this article by completing the form here.
Factors associated with readmission to alcohol and opioid detoxification in the Alaska Interior
Background and objectives: A “revolving door” of repeated admissions to detoxification treatment facilities has long plagued alcohol and drug use patients, yet few studies examine factors associated with readmission. This study examined risk factors for readmission to alcohol and opioid detoxification in a sample from the Alaska Interior.
Methods: Data were extracted from electronic medical records for admissions between 2012 and 2016 at an inpatient detoxification facility in Fairbanks, Alaska. Data from 1014 patients admitted for alcohol detoxification and 267 patients admitted for opioid detoxification were analyzed. The analysis employed descriptive statistics for risk factors (substance use history, adverse life experiences, and psychosocial functioning) and prevalence of readmission to either alcohol or opioid detoxification. Inferential analyses used marginal standardization to calculate differences in readmission risk by patient characteristics.
Results: Male, Alaska Native/American Indian, single-never married patients, and those seeking work were at higher risk for readmission to alcohol detoxification, while those with stable housing were at reduced risk. Being single-never married and completing detoxification treatment reduced readmission to opioid detoxification. Family involvement in detoxification reduced readmission risk for both alcohol and opioid patients.
Discussion and conclusions: Further research that investigates the mechanism(s) by which family may act as a protective factor may be efficacious in eliminating the “revolving door” of detoxification. Scientific significance: This study is the first to examine both alcohol and opioid use risk and protective factors in the Alaska Interior. The results can be used in the development of interventions for subpopulations with high detoxification readmission rates.
Click here to read the full article
Community members and students may request access to this article by completing the form here.
Training: Dismantling the Stigma of Substance Use and Harm Reduction Among Our Native People
This is a slide deck from the National Harm Reduction Coalition, addressing stigma of substance use and accessing harm reduction services among Native people.
Urban Indian Health Institute: Opioid Overdose & Prevention
This website’s page provides resources specific to overdose prevention in urban settings, including a map of Narcan resources near Urban Indian Organizations (UIOs).
Click here to learn more about technical assistance with the Urban Indian Health Institute (UIHI).
The Friendship House Association of American Indians Local Evaluation Report: Friendship House Healing Model and Community Defined Evidence Practice
The FH Healing Model and Community Defined Evidence Practice (CDEP) Study 2022 – 2025 utilizes a non-experimental study design, measuring variables as they naturally occur through Friendship House programs and services and studied through the lens of tribal and intertribal healing practices. The traditional healing methods for FH CDEP examination during the 3-year study period (October 1, 2022, through September 30, 2025) include Traditional Counsel (Group and Individual) Counseling, Sweat Lodge Ceremony, Talking Circle, Drum Circle, Walking the Red Road, and Cultural Gatherings. In general, the evaluation focus of the FH CDEP is to examine the effectiveness of traditional healing methods on the substance abuse treatment population of AI/AN adults who are residential clients at FH: Does the integration of AI/AN healing practices into service delivery efforts have a positive impact on program recipients’ wellness (mental, spiritual, physical and emotional), social and economic engagement, home stability, and cultural connectedness? The FH CDEP examination includes 2 process questions, 8 outcome questions, and 1 formative evaluation question.